Lipid Metabolism Practice Questions

Q: Which of the following is NOT true about Docosahexaenoic acid?

It can be synthesized in the body from linoleic acid.. **Explanation:** **1. Why Option D is the Correct Answer (The Concept):** Docosahexaenoic acid (DHA) is an **Omega-3 (ω-3)** fatty acid. It is synthesized in the body from **α-Linolenic acid (ALA)**, which is the parent 18-carbon ω-3 fatty acid. In contrast, **Linoleic acid** is the parent **Omega-6 (ω-6)** fatty acid and serves as the precursor for Arachidonic acid. Since ω-3 and ω-6 pathways are distinct and cannot be interconverted in humans, DHA cannot be synthesized from linoleic acid. **2. Analysis of Other Options:** * **Option A:** DHA is a major structural component of phospholipids in cellular membranes. It is found in exceptionally high concentrations in the **retina** (photoreceptor outer segments), **cerebral cortex** (synaptic membranes), and **sperms**, where it maintains membrane fluidity and signaling. * **Option B:** DHA is critical for the structural and functional development of the **fetal central nervous system** and visual acuity. Deficiencies during pregnancy can lead to impaired cognitive and visual outcomes. * **Option C:** Since the fetus has limited capacity to synthesize DHA from ALA, it relies on **active transplacental transport** during the third trimester. Postnatally, **breast milk** is the primary source, as most standard cow-milk formulas historically lacked DHA (though many are now fortified). **Clinical Pearls for NEET-PG:** * **Essential Fatty Acids (EFA):** Only Linoleic acid and α-Linolenic acid are "true" EFAs because humans lack Δ12 and Δ15 desaturases. * **DHA Structure:** It is a 22-carbon chain with 6 double bonds (C22:6, ω-3). * **Zellweger Syndrome:** A peroxisomal disorder where DHA synthesis is impaired (the final β-oxidation step of DHA synthesis occurs in peroxisomes), leading to severe neurological deficits.

Q: Alpha oxidation does not generate energy but is important for the brain. In which cell organelle does alpha oxidation take place?

Peroxisomes. **Explanation:** **Alpha-oxidation** is a specialized metabolic pathway required for the breakdown of **branched-chain fatty acids**, most notably **phytanic acid** (derived from chlorophyll in the diet). Unlike beta-oxidation, which occurs in the mitochondria, alpha-oxidation takes place within the **peroxisomes**. 1. **Why Peroxisomes are correct:** Branched-chain fatty acids have a methyl group at the beta-carbon, which sterically hinders the enzymes of beta-oxidation. Alpha-oxidation removes one carbon atom at a time from the carboxyl end (the alpha-carbon), bypassing this blockage. This process is vital for brain development and myelin maintenance. 2. **Why other options are incorrect:** * **Mitochondria:** This is the primary site for **beta-oxidation** of long-chain fatty acids and the TCA cycle. * **Nucleus and Nucleoli:** These organelles are involved in genetic material storage (DNA), transcription (RNA synthesis), and ribosome biogenesis; they do not participate in lipid catabolism. **High-Yield Clinical Pearls for NEET-PG:** * **Refsum Disease:** A rare autosomal recessive disorder caused by a deficiency of the peroxisomal enzyme **Phytanoyl-CoA hydroxylase**. This leads to the toxic accumulation of phytanic acid in tissues. * **Clinical Presentation:** Characterized by the triad of **retinitis pigmentosa, peripheral neuropathy, and cerebellar ataxia**. * **Key Feature:** Unlike beta-oxidation, alpha-oxidation **does not require CoA** activation and **does not generate ATP**. * **Zellweger Syndrome:** A generalized peroxisomal biogenesis disorder that also affects alpha and very-long-chain fatty acid (VLCFA) oxidation.

Q: Primary hypercholesterolemia is classified as which type according to Fredrickson's classification?

Type IIa. **Explanation:** Fredrickson’s classification (WHO classification) of hyperlipoproteinemias is based on the specific lipoprotein pattern observed in the plasma. **Why Type IIa is correct:** **Type IIa (Familial Hypercholesterolemia)** is characterized by a deficiency in **LDL receptors**, leading to an isolated elevation of **Low-Density Lipoprotein (LDL)**. Since LDL is the primary carrier of cholesterol, this results in significantly high serum cholesterol levels with normal triglycerides. Clinically, this presents with xanthelasma and tendon xanthomas. **Analysis of Incorrect Options:** * **Type I (Familial Chylomicronemia):** Caused by a deficiency of Lipoprotein Lipase (LPL) or Apo C-II. It results in elevated **Chylomicrons**, leading to severe hypertriglyceridemia, not primary hypercholesterolemia. * **Type IIb (Combined Hyperlipidemia):** Characterized by elevations in both **LDL and VLDL**. This results in high levels of both cholesterol and triglycerides. * **Type III (Dysbetalipoproteinemia):** Caused by Apo E deficiency, leading to the accumulation of **IDL (Chylomicron remnants)**. It typically presents with palmar xanthomas and elevations in both cholesterol and triglycerides. **High-Yield Pearls for NEET-PG:** * **Type IIa:** Defective LDL receptor; isolated high Cholesterol. * **Type IV:** Most common type; elevated **VLDL** (Endogenous hypertriglyceridemia). * **Type I:** Associated with eruptive xanthomas and acute pancreatitis. * **Apo B-100:** The primary apolipoprotein associated with LDL (elevated in Type II). * **Statins:** The first-line treatment for Type IIa to upregulate LDL receptors.

Q: Which of the following structures is common to all sphingolipids?

Ceramide. **Explanation:** **Why Ceramide is the correct answer:** Sphingolipids are a major class of membrane lipids derived from the 18-carbon amino alcohol **sphingosine**. When a long-chain fatty acid is attached to the amino group of sphingosine via an **amide linkage**, the resulting molecule is called **Ceramide**. Ceramide serves as the fundamental structural core and common precursor for all complex sphingolipids. Depending on the head group attached to the terminal hydroxyl group of ceramide, different sphingolipids are formed (e.g., phosphorylcholine forms Sphingomyelin; sugars form Glycosphingolipids). **Analysis of Incorrect Options:** * **A. Carnitine:** This is a quaternary ammonium compound involved in the transport of long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation (the "Carnitine Shuttle"). It is not a component of sphingolipids. * **C. Diacylglycerol (DAG):** This is the structural backbone of **Glycerophospholipids** (like lecithin), where two fatty acids are esterified to a glycerol backbone. Sphingolipids do not contain glycerol. * **D. Sphingomyelin:** While this is a sphingolipid, it is a *specific type* (a sphingophospholipid) containing a phosphorylcholine head group. It is not the "common structure" for others like cerebrosides or gangliosides. **High-Yield Clinical Pearls for NEET-PG:** 1. **Sphingolipidoses:** Deficiencies in lysosomal enzymes that break down sphingolipids lead to storage diseases. * *Niemann-Pick Disease:* Deficiency of Sphingomyelinase (accumulation of Sphingomyelin). * *Gaucher Disease:* Deficiency of β-Glucosidase (accumulation of Glucosylceramide). 2. **Key Enzyme:** Serine palmitoyltransferase is the rate-limiting enzyme in sphingosine synthesis (requires Vitamin B6). 3. **Location:** Sphingomyelin is the only phospholipid in membranes that is **not** derived from glycerol.

Q: In which organ is the maximum synthesis of fat (lipogenesis) observed?

Liver. **Explanation:** The correct answer is **Liver (Option A)**. In humans, the liver is the primary site for **de novo lipogenesis (DNL)**. This process involves the conversion of excess dietary carbohydrates (glucose) into fatty acids, which are then esterified into triglycerides. These triglycerides are packaged into Very Low-Density Lipoproteins (VLDL) and transported via the bloodstream to peripheral tissues for storage. **Why other options are incorrect:** * **Adipose tissue (Option B):** While adipose tissue is the primary site for fat **storage**, its contribution to de novo fatty acid synthesis in humans is significantly lower (approximately 10-20%) compared to the liver. In many other mammals (like rodents), adipose tissue is a major site of synthesis, which often leads to confusion. * **Intestine (Option C):** The intestine is primarily involved in the absorption of dietary fats and the assembly of **chylomicrons**, rather than the large-scale synthesis of new fatty acids from glucose. * **Muscle (Option D):** Muscles primarily utilize fatty acids for energy (beta-oxidation) or store small amounts as intramyocellular lipids; they do not perform significant lipogenesis. **High-Yield NEET-PG Pearls:** * **Rate-limiting enzyme:** Acetyl-CoA Carboxylase (ACC), which requires **Biotin** as a cofactor. * **Key Stimulator:** Insulin (promotes lipogenesis in the fed state). * **Key Inhibitor:** Glucagon and Epinephrine. * **Cellular Location:** Lipogenesis occurs in the **Cytosol**, whereas Beta-oxidation occurs in the Mitochondria. * **End product:** The primary end product of the Fatty Acid Synthase (FAS) complex is **Palmitate** (a 16-carbon saturated fatty acid).

Q: What is the rate-limiting enzyme in fatty acid synthesis?

Acetyl CoA carboxylase. **Explanation:** **Acetyl CoA carboxylase (ACC)** is the correct answer because it catalyzes the first committed and rate-limiting step of de novo fatty acid synthesis (lipogenesis). This enzyme converts Acetyl CoA into Malonyl CoA via a carboxylation reaction. This step is highly regulated: it is **activated by Citrate** (signaling high energy) and **inhibited by Palmitoyl-CoA** (feedback inhibition) and Glucagon/Epinephrine (via phosphorylation). **Analysis of Incorrect Options:** * **A. Acetoacetate synthesis:** This refers to ketogenesis, which occurs in the mitochondria during fasting or starvation, rather than fatty acid synthesis which occurs in the cytosol. * **B. Acyl transferase:** Specifically, Carnitine Acyl Transferase-I (CAT-I) is the rate-limiting enzyme for **fatty acid oxidation** (beta-oxidation), not synthesis. It is actually inhibited by Malonyl CoA to prevent a futile cycle. * **D. Biotin:** While Biotin is a vital **co-factor** for Acetyl CoA carboxylase, it is not an enzyme itself. **High-Yield Clinical Pearls for NEET-PG:** * **Co-factors required:** ACC requires **ABCs**: **A**TP, **B**iotin, and **C**O₂. * **Hormonal Control:** Insulin stimulates ACC by promoting its dephosphorylation, thereby increasing fatty acid synthesis. * **Location:** Fatty acid synthesis occurs in the **cytosol**, primarily in the liver, lactating mammary glands, and adipose tissue. * **The "Citrate Shuttle":** Since Acetyl CoA cannot cross the mitochondrial membrane, it moves to the cytosol in the form of Citrate.

Q: Hormone-sensitive lipase is not activated by which of the following?

Insulin. **Explanation:** **Hormone-sensitive lipase (HSL)** is the rate-limiting enzyme of lipolysis, responsible for mobilizing stored triglycerides from adipose tissue into free fatty acids and glycerol. Its activity is strictly regulated by covalent modification (phosphorylation). **1. Why Insulin is the correct answer:** Insulin is the primary **anabolic** hormone. It promotes fat storage and inhibits fat mobilization. Mechanistically, insulin activates **Protein Phosphatase 2**, which dephosphorylates HSL, rendering it **inactive**. Additionally, insulin activates phosphodiesterase, which lowers cAMP levels, further preventing the activation of the Protein Kinase A (PKA) pathway required for HSL activation. **2. Why the other options are incorrect:** These are **catabolic** (lipolytic) hormones that activate HSL via the cAMP-mediated phosphorylation pathway: * **Glucagon & Catecholamines (Epinephrine/Norepinephrine):** These bind to G-protein coupled receptors, increasing cAMP levels, which activates PKA. PKA then phosphorylates and **activates** HSL. * **Thyroxine (T4):** Thyroid hormones increase the sensitivity of adipocytes to catecholamines (upregulation of $\beta$-receptors), thereby indirectly promoting HSL activation and lipolysis. **High-Yield Clinical Pearls for NEET-PG:** * **Location:** HSL acts intracellularly within adipocytes. Do not confuse it with **Lipoprotein Lipase (LPL)**, which acts on the vascular endothelium to clear chylomicrons/VLDL and is *activated* by insulin. * **Perilipin:** When HSL is phosphorylated, perilipin (a protein coating the lipid droplet) is also phosphorylated, allowing HSL access to the triglyceride core. * **Glucocorticoids & ACTH:** These also stimulate lipolysis and activate HSL.

Q: Which of the following fatty acids does not belong to the omega-6 (W6) series?

Alpha linolenic acid. ### Explanation The classification of unsaturated fatty acids into **Omega (ω) series** is determined by the position of the first double bond, counting from the methyl (omega) end of the carbon chain. **Why Alpha-Linolenic Acid (ALA) is the correct answer:** Alpha-linolenic acid is an **Omega-3 (ω-3)** fatty acid. It has 18 carbons and 3 double bonds (18:3; Δ9, 12, 15). The first double bond from the methyl end is at the 3rd carbon. It is an essential fatty acid and serves as the precursor for Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA). **Analysis of Incorrect Options (Omega-6 Series):** * **Linoleic Acid (LA):** The parent fatty acid of the ω-6 series (18:2; Δ9, 12). The first double bond from the methyl end is at carbon 6. It is an essential fatty acid found in vegetable oils. * **Gamma-Linolenic Acid (GLA):** An intermediate in the ω-6 pathway (18:3; Δ6, 9, 12). It is formed from Linoleic acid by the enzyme Δ6-desaturase. * **Arachidonic Acid:** A 20-carbon ω-6 fatty acid (20:4; Δ5, 8, 11, 14). It is synthesized from Linoleic acid and serves as the primary precursor for pro-inflammatory prostaglandins and leukotrienes. **High-Yield Clinical Pearls for NEET-PG:** 1. **Essential Fatty Acids (EFA):** Humans lack the enzymes (**Δ12 and Δ15 desaturases**) to introduce double bonds beyond carbon 9; hence, Linoleic and Alpha-linolenic acids must be obtained from the diet. 2. **EFA Deficiency:** Characterized by **Phrynoderma** (follicular hyperkeratosis), scaly skin, and poor wound healing. 3. **Mnemonic:** "A**L**A is **3** letters" (Omega-3), whereas "Linoleic is **6**" (Omega-6). 4. **Arachidonic Acid:** Becomes "conditionally essential" only if its precursor, Linoleic acid, is deficient in the diet.

Q: All of the following statements are true about the regulation of cholesterol synthesis, EXCEPT?

Thyroid hormone decreases the HMG-CoA reductase activity. ### Explanation The rate-limiting step of cholesterol synthesis is the conversion of HMG-CoA to mevalonate, catalyzed by the enzyme **HMG-CoA reductase**. **Why Option D is the Correct Answer (The False Statement):** Thyroid hormone (T3/T4) actually **increases** the activity and expression of HMG-CoA reductase. However, it simultaneously increases the expression of **LDL receptors** on the liver, leading to a net effect of increased cholesterol clearance from the blood. This is why patients with hypothyroidism often present with hypercholesterolemia. **Analysis of Incorrect Options (True Statements):** * **A & B (Feedback Inhibition):** HMG-CoA reductase is regulated by end-product inhibition. Both **cholesterol** and its immediate precursor, **mevalonate**, act as feedback inhibitors to prevent the overproduction of lipids. * **C (Transcriptional Regulation):** When cellular cholesterol levels are low, **SREBP** (Sterol Regulatory Element-Binding Protein) is activated. It translocates to the nucleus and binds to the Sterol Regulatory Element (SRE), increasing the transcription of the HMG-CoA reductase gene. **High-Yield Clinical Pearls for NEET-PG:** * **Statins:** These are competitive inhibitors of HMG-CoA reductase (structural analogs of HMG-CoA). * **Hormonal Control:** Insulin and Thyroid hormones **stimulate** HMG-CoA reductase (dephosphorylated state = active), while Glucagon and Epinephrine **inhibit** it (phosphorylated state = inactive). * **AMPK:** High AMP levels (low energy) inhibit the enzyme via phosphorylation to conserve energy. * **Diurnal Rhythm:** Cholesterol synthesis is maximal at night; hence, short-acting statins are traditionally administered at bedtime.

Question 1

Which of the following is NOT true about Docosahexaenoic acid?

Accepted Answer

It can be synthesized in the body from linoleic acid.

Answer

It is found in the highest concentration in the retina, cerebral cortex, and sperms.

Answer

It is needed for the development of the fetal brain and retina.

Answer

It is supplied transplacentally and through breast milk.

Question 2

Alpha oxidation does not generate energy but is important for the brain. In which cell organelle does alpha oxidation take place?

Accepted Answer

Peroxisomes

Answer

Nucleoli

Answer

Mitochondria

Answer

Nucleus

Question 3

Primary hypercholesterolemia is classified as which type according to Fredrickson's classification?

Accepted Answer

Type IIa

Answer

Type I

Answer

Type IIb

Answer

Type III

Question 4

Which of the following structures is common to all sphingolipids?

Accepted Answer

Ceramide

Answer

Carnitine

Answer

Diacylglycerol

Answer

Sphingomyelin

Question 5

In which organ is the maximum synthesis of fat (lipogenesis) observed?

Accepted Answer

Liver

Answer

Adipose tissue

Answer

Intestine

Answer

Muscle

Question 6

What is the rate-limiting enzyme in fatty acid synthesis?

Accepted Answer

Acetyl CoA carboxylase

Answer

Acetoacetate synthesis

Answer

Acyl transferase

Answer

Biotin

Question 7

Hormone-sensitive lipase is not activated by which of the following?

Accepted Answer

Insulin

Answer

Glucagon

Answer

Catecholamines

Answer

Thyroxine (T4)

Question 8

How many ATP molecules are formed from one complete cycle of beta-oxidation?

Accepted Answer

5

Answer

3

Answer

7

Answer

12

Question 9

Which of the following fatty acids does not belong to the omega-6 (W6) series?

Accepted Answer

Alpha linolenic acid

Answer

Linoleic acid

Answer

Arachidonic acid

Answer

Gamma linolenic acid

Question 10

All of the following statements are true about the regulation of cholesterol synthesis, EXCEPT?

Accepted Answer

Thyroid hormone decreases the HMG-CoA reductase activity

Answer

HMG-CoA reductase is inhibited by mevalonate

Answer

HMG-CoA reductase is inhibited by cholesterol

Answer

SREBP increases the transcription of HMG-CoA reductase

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?